Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients

What the order contains

Section headings exactly as they appear in the official text.

• Sec. 1. Purpose
• Sec. 2. Policy
• Sec. 3. Addressing Foreign Nations Freeloading on American-Financed Innovation
• Sec. 4. Enabling Direct-to-Consumer Sales to American Patients at the Most-Favored-Nation Price
• Sec. 5. Establishing Most-Favored-Nation Pricing
• Sec. 6. General Provisions

Section 1, quoted from the order

Verbatim text from the signed document. These are the words of the document, not SaveYourState’s.

The United States has less than five percent of the world's population and yet funds around three quarters of global pharmaceutical profits. This egregious imbalance is orchestrated through a purposeful scheme in which drug manufacturers deeply discount their products to access foreign markets, and subsidize that decrease through enormously high prices in the United States. The United States has for too long turned its back on Americans, who unwittingly sponsor both drug manufacturers and other countries. These entities today rely on price markups on American consumers, generous public subsidies for research and development primarily through the National Institutes of Health, and robust public financing of prescription drug consumption through Federal and State healthcare programs. […]

Federal Register notes

See: EO 14273, April 15, 2025